A patient-derived xenograft mouse model generated from primary cultured cells recapitulates patient tumors phenotypically and genetically

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 9, 2013, Pages 1471-1480

  Seol, Hyang Sook ^a   Suh, Young Ah ^a,b   Ryu, Young Joon ^a   Kim, Hyun Jung ^a   Chun, Sung Min ^a   Na, Deuk Chae ^a   Fukamachi, Hiroshi ^c   Jeong, Seong Yun ^a,b   Choi, Eun Kyung ^a,b   Jang, Se Jin ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Lung cancer; OncoMap; Patient derived primary cancer cells; Xenograft model

Indexed keywords

CD56 ANTIGEN; CHROMOGRANIN; CYTOKERATIN 20; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CASE REPORT; CONTROLLED STUDY; CULTURE MEDIUM; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LUNG CANCER; MALE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PERSONALIZED MEDICINE; PHENOTYPE; PRIMARY CANCER CELL; PRIORITY JOURNAL; SCID MOUSE; TRANSLATIONAL RESEARCH; TUMOR GENE; TUMOR XENOGRAFT;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; CARCINOMA, ADENOSQUAMOUS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; MUTATION; PHENOTYPE; PRIMARY CELL CULTURE; SMALL CELL LUNG CARCINOMA; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882606759     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1449-6     Document Type: Article

References (25)

1. Anguiano A, Nevins JR, Potti A (2008) Toward the individualization of lung cancer therapy. Cancer 113:1760-1767
2. Azzoli CG, Park BJ, Pao W, Zakowski M, Kris MG (2008) Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: A time for excitement and equipoise. J Thorac Oncol 3:84-93
3. Bepler G, Begum M, Simon GR (2008) Molecular analysis-based treatment strategies for non-small cell lung cancer. Cancer Control 15:130-139
4. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabro E, Pastorino U, Sozzi G (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106:16281-16286
5. Cree IA, Glaysher S, Harvey AL (2010) Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 10:375-379
6. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M, Peacock CD, Watkins DN (2009) A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 69:3364-3373
7. De Witt Hamer PC, Van Tilborg AA, Eijk PP, Sminia P, Troost D, Van Noorden CJ, Ylstra B, Leenstra S (2008) The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27:2091-2096 (Pubitemid 351442747)
8. Dong X, Guan J, English JC, Flint J, Yee J, Evans K, Murray N, Macaulay C, Ng RT, Gout PW, Lam WL, Laskin J, Ling V, Lam S, Wang Y (2010) Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res 16:1442-1451
9. Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM (2012) The role of PI3 K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Anticancer Res 32:2531-2536
10. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367-1380
11. Hodkinson PS, Mackinnon AC, Sethi T (2007) Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol 83:733-741 (Pubitemid 350219111)
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009 CA: A cancer journal for clinicians 59: 225-249
13. John T, Kohler D, Pintilie M, Yanagawa N, Pham NA, Li M, Panchal D, Hui F, Meng F, Shepherd FA, Tsao MS (2011) The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res 17:134-141
14. John T, Yanagawa N, Kohler D, Craddock KJ, Bandarchi-Chamkhaleh B, Pintilie M, Sykes J, To C, Li M, Panchal D, Chen W, Shepherd FA, Tsao MS (2012) Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. J Thorac Oncol 7:1101-1108
15. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P, Landron S, Bigot L, Nemati F, Cuilliere-Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierre A, De The H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prevost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C (2012) Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res: An official journal of the American Association for Cancer Research
16. Kerbel RS (2003) Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2:S134-S139
17. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA (2009) Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4:e7887
18. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, Poupon MF (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13:3989-3998 (Pubitemid 47037607)
19. Merk J, Rolff J, Becker M, Leschber G, Fichtner I (2009) Patient-derived xenografts of non-small-cell lung cancer: A pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg 36:454-459
20. Moro M, Bertolini G, Tortoreto M, Pastorino U, Sozzi G, Roz L (2012) Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J Biomed Biotechnol 2012:568567
21. Pandita A, Aldape KD, Zadeh G, Guha A, James CD (2004) Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39:29-36 (Pubitemid 37475250)
22. Rubio-Viqueira B, Hidalgo M (2009) Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 85:217-221
23. Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350:379-392 (Pubitemid 38101633)
24. Wehenkel M, Ban JO, Ho YK, Carmony KC, Hong JT, Kim KB (2012) A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer 107:53-62
25. Yoshimasu T, Ohta F, Oura S, Tamaki T, Shimizu Y, Naito K, Kiyoi M, Hirai Y, Kawago M, Okamura Y (2009) Histoculture drug response assay for gefitinib in non-small-cell lung cancer. Gen Thorac Cardiovasc Surg 57:138-143